source
- J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroupJohnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
- Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's TepezzaViridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…